How Do Peptides Work? A Beginner’s Guide to Peptide Mechanisms

By NorthPeptide Research Team · April 5, 2026

What Are Peptides?

Peptides are molecules made of amino acids linked together in a chain. Amino acids are the fundamental building blocks of biological life — there are 20 standard ones encoded by the human genome, and they form the backbone of every protein in your body. When two or more amino acids join together through a peptide bond (a covalent bond between the carboxyl group of one amino acid and the amino group of the next), the resulting molecule is called a peptide.

The size distinction matters in research:

• Dipeptides: 2 amino acids
• Tripeptides: 3 amino acids
• Oligopeptides: 4–20 amino acids (a common range for research peptides)
• Polypeptides: 20–50+ amino acids
• Proteins: Generally 50+ amino acids, often folded into complex three-dimensional structures

Most research peptides fall in the oligopeptide to polypeptide range. BPC-157, for example, is a 15-amino-acid peptide. Retatrutide is 39 amino acids. Semaglutide is 31 amino acids. The relatively small size of peptides compared to full proteins has important implications for how they interact with biological systems — and for how they need to be handled in the lab.

How Peptides Differ From Proteins

The line between a peptide and a protein is partly about size, but also about function and structure. Proteins are large, complex molecules that fold into intricate three-dimensional configurations. That folding is essential to their function — a misfolded protein is often non-functional or actively harmful, as in prion diseases. Peptides, being smaller, tend to be more linear or only partially structured, and their biological activity typically depends on a shorter recognition sequence rather than a full three-dimensional conformation.

This structural difference has practical implications for research:

• Stability: Peptides are generally more susceptible to degradation by enzymes called proteases and peptidases, which cleave peptide bonds. Synthetic peptides used in research are often modified with non-natural amino acids (like aminoisobutyric acid, Aib) or lipid conjugations specifically to resist this degradation.
• Synthesis: Peptides can be manufactured using solid-phase peptide synthesis (SPPS), a well-established chemical process that builds the amino acid chain from scratch. This makes large-scale production feasible in ways that protein biologics are not.
• Receptor targeting: The relatively small size of peptides allows them to be designed or discovered as highly specific ligands for particular receptor binding pockets, making them precise molecular tools.

Receptor Binding: The Lock and Key

Most research peptides work by binding to specific receptors — proteins on the surface of cells (or inside them) that are designed to receive particular molecular signals. The classic model is often described as a lock-and-key: the receptor is the lock, and the peptide (or its natural analog) is the key. When the right key enters the right lock, the door opens — meaning an intracellular signaling cascade is triggered.

In practice, the relationship is more like an “induced fit” model: the receptor and ligand are both somewhat flexible, and the binding of the peptide causes conformational changes in the receptor that activate it. The binding site on a receptor is called the orthosteric site (the primary active site). Some compounds bind to allosteric sites — locations separate from the main binding pocket that nonetheless modulate receptor activity.

Agonists vs. Antagonists vs. Modulators

When a peptide binds to a receptor, the outcome depends on what it does to that receptor:

• Agonist: Binds to the receptor and activates it, mimicking or exceeding the effect of the natural ligand. GLP-1 receptor agonists like semaglutide and retatrutide are agonists — they activate the GLP-1 receptor in ways similar to, but often stronger than, the native hormone GLP-1.
• Antagonist: Binds to the receptor but does not activate it, blocking the natural ligand from binding. Antagonists effectively silence a receptor pathway.
• Partial agonist: Binds and partially activates the receptor — producing some effect, but less than a full agonist even at saturating concentrations.
• Biased agonist: Activates the receptor but preferentially triggers some downstream signaling pathways over others. Tirzepatide is thought to be a biased agonist at the GIP receptor, which may partly explain why its effects differ from those of native GIP.

Signal Transduction: What Happens After Binding

Receptor binding is only the beginning. The receptor must translate the extracellular signal (the peptide) into an intracellular response. This process is called signal transduction, and it involves a series of molecular relay steps that ultimately change what the cell does.

Most research peptides act on one of three major classes of cell-surface receptors:

G Protein-Coupled Receptors (GPCRs)

The vast majority of peptide hormone receptors — including GLP-1R, GIPR, GCGR, GHRH-R, ghrelin receptor (GHSR), and many others — are GPCRs. When a peptide binds to a GPCR, it causes a conformational change that activates an associated G protein (a molecular switch) on the inside of the cell membrane. The activated G protein then modulates intracellular messengers:

• cAMP pathway: Gs-coupled receptors (like GLP-1R) activate adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates numerous target proteins to alter cell behavior. For beta cells, this cascade potentiates insulin secretion in response to glucose.
• PKC pathway: Gq-coupled receptors activate phospholipase C (PLC), which generates diacylglycerol (DAG) and inositol trisphosphate (IP3), leading to calcium release and protein kinase C (PKC) activation.
• Gi pathway: Gi-coupled receptors inhibit adenylyl cyclase, reducing cAMP levels and suppressing downstream signaling.

After a GPCR is activated, cells have mechanisms to down-regulate its activity — a process called receptor desensitization. Beta-arrestins bind to phosphorylated GPCRs, uncoupling them from G proteins and triggering receptor internalization. Biased agonism research often focuses on designing peptides that preferentially activate the cAMP arm of GPCR signaling while minimizing beta-arrestin recruitment, potentially improving the therapeutic window.

Receptor Tyrosine Kinases (RTKs)

Some peptides signal through receptors that have intrinsic kinase activity. The insulin receptor and IGF-1 receptor are the most relevant examples in peptide research. When insulin or IGF-1 binds to these receptors, the receptor dimerizes and autophosphorylates, creating docking sites for intracellular signaling proteins. Key downstream pathways include the PI3K/AKT pathway (involved in cellular survival, glucose uptake, and protein synthesis) and the MAPK/ERK pathway (involved in cell proliferation).

IGF-1 LR3, a synthetic analog of IGF-1 found in research catalogs, works through this RTK system — its extended amino acid sequence reduces its affinity for IGF-1-binding proteins, extending its effective half-life in research settings.

Nuclear Receptors

Some signaling molecules (notably steroid hormones) work by crossing the cell membrane and binding to receptors inside the nucleus, directly regulating gene transcription. Most peptides do not operate through nuclear receptors because they cannot easily cross the lipid bilayer of the cell membrane. However, some smaller peptide fragments and certain research compounds (like AICAR, which affects AMPK signaling) work through intracellular pathways.

Major Categories of Research Peptides and How They Work

Research peptides span a wide range of mechanisms. The major categories relevant to the current research landscape include:

Growth Hormone Secretagogues (GHS)

These peptides stimulate the release of growth hormone from the anterior pituitary gland, either by mimicking growth hormone-releasing hormone (GHRH) or by acting on ghrelin receptors. The two main subclasses are:

• GHRH analogs — Peptides like sermorelin and CJC-1295 mimic the natural GHRH hormone, binding to GHRH receptors in the pituitary and stimulating GH release through the cAMP/PKA cascade. Because they work through the body’s natural GH regulatory axis, GH pulses remain physiologically patterned.
• Ghrelin mimetics (GHRPs) — Peptides like GHRP-2, GHRP-6, hexarelin, and ipamorelin bind to the ghrelin receptor (GHSR-1a). They activate a distinct intracellular pathway (Gq/PKC) and tend to produce strong GH pulses. Some also have additional effects: GHRP-6 stimulates appetite significantly via ghrelin receptor activity, while ipamorelin is noted for high receptor selectivity with minimal effects on cortisol or prolactin in research models.

GLP-1 and Incretin Receptor Agonists

These peptides activate incretin hormone receptors involved in glucose regulation and energy metabolism. They range from single-target (semaglutide, GLP-1R only) to dual-target (tirzepatide, GLP-1R + GIPR) to triple-target (retatrutide, GLP-1R + GIPR + GCGR). All act as GPCRs through the Gs/cAMP pathway, but the combination of receptor targets produces distinct metabolic profiles. This is the most active area of pharmaceutical peptide research as of 2026.

Tissue-Repair and Protective Peptides

Peptides like BPC-157 (Body Protection Compound, a 15-amino-acid sequence derived from human gastric juice), TB-500 (a synthetic fragment of thymosin beta-4), and GHK-Cu (a copper-binding tripeptide) have been investigated in preclinical models for effects on tissue healing, angiogenesis, and cellular protection. Their mechanisms are more complex and less fully characterized than the incretin agonists — BPC-157 appears to interact with multiple receptor systems including the nitric oxide system and growth factor pathways, while TB-500 is thought to work partly by binding to actin and modulating cytoskeletal dynamics (PubMed, BPC-157 review).

Bioregulator Peptides (Khavinson Peptides)

A distinct class of short peptides (typically 2–4 amino acids) developed from research by Dr. Vladimir Khavinson and colleagues in Russia. These include epithalon (Ala-Glu-Asp-Gly), a tetrapeptide originally derived from the pineal gland, and thymulin (a nonapeptide from the thymus). The proposed mechanism involves direct interaction with gene promoter regions — these peptides are small enough to potentially enter cells and bind to DNA, acting as transcription regulators. This is a mechanistically distinct pathway from receptor-mediated signaling and remains an area of active investigation, with most published research originating from Khavinson’s institute in St. Petersburg.

Melanocortin Receptor Peptides

Peptides like melanotan I and melanotan II, as well as PT-141 (bremelanotide), act on melanocortin receptors (MC1R, MC3R, MC4R). MC1R activation on melanocytes stimulates melanin synthesis, the mechanism underlying their investigation in tanning and skin pigmentation research. MC4R, expressed in the hypothalamus, is involved in sexual function and appetite regulation. PT-141 differs from melanotan II in having been developed specifically for MC4R-mediated effects (PubMed, melanocortin receptors).

Antimicrobial Peptides

A class of peptides — including LL-37, the only known human cathelicidin — that exhibit broad-spectrum antimicrobial activity. Their mechanism is primarily membrane disruption: the peptides are cationic (positively charged) and amphipathic (having both hydrophilic and hydrophobic regions), allowing them to insert into the negatively charged membranes of bacteria and form pores that cause cell death. Unlike conventional antibiotics that target specific bacterial enzymes, membrane-disrupting peptides are less susceptible to the conventional mechanisms of antibiotic resistance, making them of interest in antimicrobial research (PubMed, LL-37 review).

Bioavailability: The Delivery Problem

One of the most important practical considerations in peptide research is bioavailability — the fraction of an administered compound that reaches its site of action in an active form. Peptides face a fundamental challenge: the gastrointestinal tract is specifically designed to break them down. Proteases and peptidases in the stomach and small intestine cleave peptide bonds, reducing most peptides to their component amino acids before they can be absorbed. This is why most research peptides are administered by subcutaneous or intravenous injection, bypassing the digestive system entirely.

Pharmaceutical chemists use several strategies to improve peptide stability and extend half-life:

• Non-natural amino acid substitutions: Replacing natural L-amino acids with D-amino acids or unusual analogs like aminoisobutyric acid (Aib) makes the peptide harder for enzymes to recognize and cleave. This is why semaglutide has an Aib substitution at position 8 — native GLP-1 is cleaved there by DPP-4 within minutes, but the Aib-modified version is resistant.
• Lipid conjugation: Attaching a fatty acid chain (as with semaglutide’s C18 chain or retatrutide’s C20 fatty diacid) allows the peptide to bind reversibly to serum albumin. Albumin-bound peptide acts as a circulating reservoir, dramatically extending the half-life from minutes to days.
• PEGylation: Attaching polyethylene glycol (PEG) chains increases molecular size and reduces renal clearance, extending half-life. Less common in modern research peptides as lipid conjugation has proven more effective for many applications.
• Cyclization: Forming a ring structure (either head-to-tail or through side-chain linkages) can increase conformational rigidity and resistance to proteolysis.
• Absorption enhancers (oral delivery): Semaglutide oral (Rybelsus) uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to locally raise gastric pH and facilitate transcellular absorption — a pharmaceutical breakthrough for oral peptide delivery, though bioavailability remains very low (~0.4–1%).

For most research peptides in laboratory settings, subcutaneous injection with reconstitution in bacteriostatic water or sterile saline remains the standard administration method. Lyophilized (freeze-dried) peptide powder should be stored at -20°C and reconstituted shortly before use, then refrigerated at 2–8°C for short-term storage.

Why Specificity Matters in Peptide Research

One of the reasons researchers find peptides valuable as molecular tools is their potential for high receptor specificity. Because the binding of a peptide to its receptor depends on a precise three-dimensional fit — both the shape of the peptide and the complementary shape of the binding pocket — well-designed peptides can be highly selective for a single receptor subtype even within a family of closely related receptors. This specificity allows researchers to dissect individual receptor pathways more cleanly than with small-molecule drugs, which often have off-target effects due to their simpler structures.

However, selectivity is not guaranteed. Some peptides, particularly shorter ones, may bind to multiple receptors. Some synthetic analogs may have different selectivity profiles than their natural counterparts. Understanding the receptor pharmacology of any research peptide — including its EC50 values at target and off-target receptors, its agonist versus antagonist properties, and any known biased signaling characteristics — is essential context for interpreting experimental results.

References:

• Sikiric et al. “Stable gastric pentadecapeptide BPC 157.” Current Pharmaceutical Design, 2018.
• Wikberg JE. “Melanocortin receptors: new opportunities in drug discovery.” Expert Opinion on Therapeutic Patents, 2001.
• Hancock RE, Haney EF, Gill EE. “The immunology of host defence peptides.” Nature Reviews Immunology, 2016.
• Jastreboff et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” NEJM, 2023.
• “Retatrutide: Game Changer in Obesity Pharmacotherapy.” PMC.